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A B S T R A C T
Background: Breast cancer (BC) is the main cause of cancer mortality among women, and mortality from
lung cancer (LC) is increasing among women. The purpose of the present study was to project the
mortality rates of both cancers and predict when LC mortality will exceed BC mortality.
Methods: The cancer mortality data and female population distribution were obtained from the Spanish
National Statistics Institute. Crude rate (CR), age-standardized rate (ASR), and age-speciﬁc rate were
calculated for the period 1980–2013 and projected for the period 2014–2020 using a Bayesian log-linear
Poisson model.
Results: All calculated rates were greater for BC than for LC in 2013 (CR, 27.3 versus 17.3; ASR, 13.5 versus
9.3), and the CR was not projected to change by 2020 (29.2 versus 27.6). The ASR for LC is expected to
surpass that of BC in 2019 (12.9 versus 12.7).
Conclusions: By 2020 the LC mortality rates may exceed those of BC for ages 55–74 years, possibly because
of the prevalence of smoking among women, and the screening for and more effective treatment of BC. BC
screening could be a good opportunity to help smokers quit by offering counseling and behavioral
intervention.
ã 2016 Elsevier Ltd. All rights reserved.
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Cancer is among the leading causes of morbidity and mortality
worldwide, with approximately 14 million new cases and
8.2 million cancer-related deaths in 2012 [1]. The leading cancers
are lung, prostate, colorectal, stomach, and liver among men and
breast, colorectal, lung, cervix, and stomach among women [2].
The incidence age-standardized rate (ASR) of breast cancer (BC)
in women varies widely, from 19.3 in Eastern Africa to 89.7 in
Western Europe [3]. The 5-year relative survival is over 80% in
developed countries [4], which usually have more extensive* Corresponding author at: Biostatistics Unit, Department of Basic Sciences,
Universitat Internacional de Catalunya, Carrer de Josep Trueta s/n 08195 Sant Cugat
del Vallès, Barcelona, Spain.
E-mail address: jmmartinez@uic.es (Dr. J.M. Martínez-Sánchez).
http://dx.doi.org/10.1016/j.canep.2016.05.009
1877-7821/ã 2016 Elsevier Ltd. All rights reserved.screening programs. Thus far, mammography is the only screening
program proven to be effective for BC, but it is only possible in
countries with the appropriate health infrastructure [5]. The most
common treatments can be classiﬁed as local therapies (treating
the tumor at the site), such as surgery and radiation, or systemic
therapies (to reach cancer cells anywhere in the body), such as
hormone and targeted therapy.
The incidence ASR of lung cancer (LC) in women is lower than
the incidence rate of BC, ranging from 0.9 in Central Africa to
35.8 in North America [3]. However, LC has a worse survival
prospect, with a 5-year net survival under 20% in developed
countries [6,7] and a 5-year relative survival of 13% in Europe [8]; it
is the leading cause of cancer mortality [2]. At diagnosis, most LC
patients have an advanced stage of disease, which is associated
with poorer prognosis. The most common LC screening tests for
early detection are chest x-ray, sputum cytology, and low-dose
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with a reduction of 20% of mortality in a study in the United States
[9]; still, LDCT identiﬁes a high number of false positives with
harmful implications. Moreover, there is no evidence of a reduction
in the smoking prevalence among those screened [10–12]. The
poor prognosis at the time of detection of the LC provides greater
value to primary prevention for lowering mortality.
In Europe, cancer mortality per year for women decreased by 1%
from 1993 to 2009, with the exceptions of lung and pancreatic
cancers which increased during the same period of time [13].
Moreover, the incidence of major tobacco-related cancers,
including LC, have increased for women in Europe [14]. These
opposite trends between LC and BC imply an important reduction
in the difference in the mortality of both cancers (2009: an
observed ASR of 13.05 by LC versus 15.85 by BC; 2015: a predicted
ASR of 14.24 by LC versus 14.22 by BC) [15].
In Spain, a similar pattern has been observed: the cancer
mortality in women has decreased, with the exceptions of LC and
BC which lead the mortality rate [16]. In 2012, the incidence ASR
estimates were 67.3 for BC and 11.3 for LC, and the mortality ASR
estimates were 11.3 and 9.4 [17]. The BC mortality in Spain is one of
the lowest in Europe; it was low at the end of the 1980s and is
decreasing faster than the European average [18]. The LC mortality
is low compared to the rest of Europe but has been increasing faster
in the last few years. This suggests that LC mortality among women
could surpass BC mortality in Spain in the next few years.
Moreover, the shape of the Spanish population pyramid has
changed in the last 20 years. The proportion of subjects aged >65
years was 10% in 1975 and 17% in 2010, and the prospect is that this
will grow to 32% in the coming 40 years [19]. Spain is one of the
countries with higher life expectancy in the world, and Spanish
women have a high life expectancy at birth (85 years) [20].
The objectives of this study were to project the mortality rates
of LC and BC in women in Spain and to predict when LC mortality
will exceed BC mortality.
2. Methods
2.1. Data sources
The data were obtained from the National Statistics Institute
(INE) [21]. Mortality data were available for women during the
period 1980–2013. Deaths due to LC and BC were grouped by year
and age (18 groups, from 0 to 4 years to 85 or more years).
Population data were also available during the study period, and
future population estimations were obtained from 2014 to
2020 and provided by the INE.
2.2. Outcomes
For each age group we calculated the crude mortality rate (CR),
the ASR using the direct method with the world standard
population [22], and the age-speciﬁc mortality rate for the
following groups: 45–54 years, 55–64 years, 65–74 years, and
75 years. All rates were calculated for LC and BC in women and
reported as per 100,000 person years.
2.3. Statistical analysis
A log-linear model was used to predict the future mortality
rates of LC and BC in women. Assuming the number of deaths for
the ith age group and the tth year following a Poisson distribution of
average mi,t the following Bayesian model was suggested accordingto previous studies [23,24]:
mi;t
Yi;t
¼ e aiþbi ttoð Þð Þ;
where Yi,t is the population and t0 is the reference year. Note that
(eb 1) is the annual percentage change (APC) in the mortality
rate. This value is a good indicator of the trend in the rate; the sign
indicates an increase (positive) or decrease (negative) and the
magnitude indicates the intensity of the trend [23].
By applying a Bayesian model we avoid ﬁtting problems in
those age groups with low rates and small counts of deaths, as it
could happen in a classical approach making use of a similar model,
and even in this situation one could produce predictive and
credible intervals. Before applying the model, two decisions must
be made: the number of years used to estimate the model and the
number of years predicted. Using all available years is not
necessarily the best option to obtain the best model, as the
condition of log-linearity in the model could not be met. In
contrast, models created from a small number of years can best
meet the condition of log-linearity, but they produce estimates
with poor accuracy. Evidence suggests that the linear trend of LC
mortality has not changed since 2007 in any age group [25]. On the
other hand, the most reliable prediction base for a log-linear model
could be 5 years, with 10 years or more not covering the observed
number of deaths [26]. According to these points, we have ﬁtted
our model to the period 2007–2013 and used it to predict rates
during the period 2014–2020. Regarding the predictions, as we
move forward in time the compliance of the log-linear assumption
becomes questionable and the precision decreases.
A Gaussian distribution as prior was applied for all ai and bi so
ai normal (0, ta) and bi normal (0, tb) with precision
parameters ta and tb having ﬂat hyper-priors ta gamma
(c, f) and tb gamma (c, f), where c = f = 0.001. The models
were implemented using WINBUGS and run in R [27,28]. Each
model was generated by a Markov Chain Monte Carlo run of three
chains of 25,000 values, discarding the ﬁrst 5,000 as a burn-in
process and keeping every second. The chains differentiated for the
initial values of ta and tb (1 in the ﬁrst chain, 0.1 in the second
chain, and 10 in the third chain) and an initial value for all ai and bi
obtained from a normal distribution of mean 0 and precision 0.01.
Therefore, we obtained 30,000 samples of the model parameters,
which allowed us to predict the future number of deaths by LC and
BC in each age group. Once the predicted number of deaths was
obtained, the distribution of the mortality rates could be described.
The results were reported as the median and the 95% credible
interval (95% CI) predicted for LC and BC each year in the period
2014–2020. We reported all mortality rates, the annual percentage
change in the mortality rate by age group, and the LC/BC ratio for
the calculated rates. If the 95% CI of the ratio included 1, we
assumed that the LC and BC rates did not differ.
2.4. Comparison of the cumulative risk of death
We calculated the cumulative rate (C) for LC and BC for the years
2013 and 2020 by adding age-speciﬁc absolute rates (in 5-year age
groups) and then the lifetime cumulative risk up to 80 years of age
using the following standard formula:
100 1  e5 C105
 
The cumulative risk may be interpreted as the probability that
an individual will die from the cancer of interest before a certain
age (up to 80 years in our analysis) in the absence of competing
causes of death [29].
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Table 1 and Fig. 1 show the LC and BC mortality rates in women
between 1980 and 2013 and the projections for 2014–2020.
The LC mortality rates clearly increased during the period
1980–2013 (Table 1) starting in the mid-1990s (Fig. 1). In
2007–2013, the period used to estimate the model, all rates also
increased approximately 5% annually (CR: 12.3 to 17.3 and ASR: 7.0
to 9.3), whereas the maximal increase in age-speciﬁc rates was 10%
for the 55–64 age group (21.1 to 37.0).
BC mortality rates were lower in 2013 than in 1980 (with the
exception of the CR and for those aged 75 years). The rates
increased until the ﬁrst half of the 1990s but decreased thereafter
(Fig. 1). During the period 2007–2013 there were small variations
not greater than 10%, with an increased CR (26.4 to 27.3) and age-
speciﬁc rates for those aged 75 years (113.6 to 115.7), the others
decreasing approximately 1.5% annually.
The predicted LC mortality for 2014–2020 showed an increase.
The ASR would exceed 10 (95% CI 10.3–11.5) in 2016 and would be
just under 15 in 2020 (95% CI 12.6–14.7). The CR would exceed 20
in 2017 (95% CI 21.2–23.56), almost reaching 30 in 2020 (95% CI
25.7–29.6). The predicted BC mortality indicates a slow increase in
the CR, which will be below 30 until 2016 (95% CI 27.2–29.3) but
will be greater later (2020: 95% CI 27.7–30.7), and a slow decrease
in the ASR, which will be over 12 until 2018 (95% CI 12.2–13.4)
(Table 1).
Fig. 2 shows the different patterns in the APC according to age
group for both cancers, modeled from observations during the
period 2007–2013. The 95% CI shows an increase of over 3% and up
to 12% in LC for the 55–74 age group. The APC in BC mortality
according to age group has an estimate below 0 with a 95% CI
which includes 0, the exceptions being the age group 80–84, where
the estimate is above 0, and the age group 45–49 where the 95% CI
does not include 0.
Table 2 shows the LC/BC ratios for all predicted mortality rates
reported as the median and 95% CI. LC will reach and even exceed
BC in the next few years, but not in all predicted rates. The 95% CI
was >1 for the 55–64 age group from 2015 (95% CI 1.05–1.34), and
the 65–74 age group from 2019 (95% CI 1.05–1.49). The 95% CI
included 1 for the CR from 2020 (95% CI 0.86–1.03), the ASR from
2018 (95% CI 0.88–1.03), and the 45–54 age group from 2019 (95%
CI 0.68–1.03). The 95% CI ratio was <1 from 2014 to 2020 in the age
group 75 years (2020: 95% CI 0.49–0.64).
Fig. 3 shows the cumulative risk of BC and LC death up to
80 years of age, comparing the years 2013 and 2020. The
cumulative risk of BC death was higher than that of LC in all age
groups during 2013, reaching 2.23% at up to 80 years of age
(Fig. 3a). On the basis of the predicted age-speciﬁc BC and LC
mortality rates in 2020, the cumulative risk of LC death could
surpass that of BC for those between 55 and 75 years of age
(Fig. 3b). The difference in the cumulative risks of death between
the years 2020 and 2013 shows a decreasing risk of BC death in all
age groups but an increasing cumulative risk of LC death beyond
45 years of age (Fig. 3c).
4. Discussion
The predictions indicate that the mortality rate for LC will reach
and/or exceed the mortality rate for BC in the next few years, and
that LC will become the leading type of cancer mortality for
women in Spain. If not for all ages, it has been well established for
women 55–64 years of age (expected from 2014). A study in the
European Union predicted that LC mortality would slightly exceed
BC mortality in 2015, not in the number of deaths but in the ASR,
but for Spain BC mortality is still predicted to be greater than LC
Fig. 1. Observed rate (per 100,000 people years) of breast cancer (continuous lines) and lung cancer (dashed lines) mortality (1980–2013) and median for the projected rates
(per 100,000 people years) in the period 2014–2020.
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used from a JoinPoint Regression [15].
Sincethe1980s, BChas beenthe ﬁrst causeofdeathfromcancerin
women in Spain, but mortality rates decreased by 1.8% from 1997 to
2006 [30]. This downward trend can be attributed to treatment and
screening programs. Since the 1980s there have been continuous
advancements in treatment, such as the use of adjuvant therapy to
reduce the risk of BC recurrence [31], new chemotherapy drugs to
slow cancer growth [32], and the introduction of sentinel-lymph-
node biopsy to assess BC spread [33]. Currently, clinicians approachthis diseasewith a rapidlyevolving multidisciplinary treatment [34].
BC screening is the second key factor to explain the decrease in BC
mortality. The age group considered for breast screening in Spain is
45 or 50 to 70 years depending on the autonomous community (AC),
and the geographical coverage is 100% according to international
recommendations. Screening was initiated in 1990 in Navarre and
progressively implemented in all the ACs. Women of
50–64 years of age are included in all programs, starting at 45 years
or ﬁnishing at 69 years in some ACs. The mean overall participation
was 67.0% [35]. Spain currently has a lower BC mortality rate among
Fig. 2. Median and 95% credible interval of annual percentage change in lung cancer and breast cancer mortality by age group in the period 2007–2013.
26 J.C. Martín-Sánchez et al. / Cancer Epidemiology 43 (2016) 22–29the European countries [18,36]. Undoubtedly, the coverage of BC
screening has been successful and screening should be used in other
diseases when possible.
On the other hand, the breast cancer mortality is still increasing
in older women (75 years), as previously observed in other
studies [37]. In the analysis by 5-year age groups, mortality rates
are increasing only in the 80–84 years group, though not
signiﬁcantly. The difference in the patterns observed between
women 50–74 years old and those over 75 years could be partially
explained by the different years of implementation of breast
cancer screening programs across 17 autonomous regions of Spain
[37] and the lower participation rate in the ﬁrst years of breast
cancer screening in Spain [38]. As a result of this, a smaller
proportion of older women may have beneﬁted from the breast
screening program, which may result in less favorable mortality
trends.
The main risk factor for LC is tobacco consumption [39]. Time
trends for tobacco use could predict the incidence and mortality of
LC [40]. However, there is a gap in time between the beginning of
smoking habits and the diagnosis of LC; when smoking prevalenceTable 2
Median (95% credible intervals, 95% CIs) for the ratio of lung cancer and breast cancer
Type of rate 2014 2015 2016 
Crude rate 0.66 (0.63–0.70) 0.70 (0.66–0.74) 0.74 (0.70–0.79) 
Age-standardized rate 0.74 (0.70–0.78) 0.78 (0.73–0.83) 0.83 (0.78–0.89) 
45 to 54 y 0.74 (0.64–0.84) 0.76 (0.65–0.87) 0.77 (0.66–0.91) 
55 to 4 y 1.07 (0.96–1.20) 1.18 (1.05–1.34) 1.31 (1.15–1.49) 
65 to 74 y 0.87 (0.78–0.98) 0.94 (0.83–1.06) 1.01 (0.88–1.15) 
75 y 0.49 (0.45–0.53) 0.49 (0.45–0.53) 0.51 (0.46–0.56) 
Bolded if the 95% credible interval is over 1.
Italics if the 95% credible interval is under 1.decreases the mortality due to LC may still increase because of the
effect of previous smoking. The gap between the smoking
prevalence rates and the smoking-caused mortality is estimated
to be approximately 30–40 years [40], with the highest correlation
for women with a lag of 40 years [41]. The actual increase in LC
mortality rates among women could be explained by 40 years
having passed since the 1970s, when the prevalence of tobacco use
increased the most, from 5.8% in 1970 to 15.0% in 1980 [42],
reaching 26.5% in 1990 and leveling off until the 2000s, when it
started to decrease [41]. The gap of 40 years and the maximum
smoking prevalence achieved in the early 1990s indicate that the
maximum age-adjusted mortality could be achieved around 2030.
This is in line with our projections of increasing age-adjusted rates
in the analyzed period (2014–2020).
No population screening program is currently available for LC in
Spain [43]. If such a program was implemented, the usual target
population would be actual smokers 50–74 years of age who smoke
at least 20 cigarettes per day. The program could also include
ex-smokers from the last 10–15 years. This approach would
include approximately 400,000 women and 900,000 men [10]. The mortality for the projected rates in the period 2014–2020.
2017 2018 2019 2020
0.78 (0.73–0.84) 0.83 (0.77–0.90) 0.88 (0.82–0.96) 0.94 (0.86–1.03)
0.89 (0.83–0.96) 0.95 (0.88–1.03) 1.01 (0.93–1.11) 1.08 (0.99–1.19)
0.79 (0.67–0.94) 0.82 (0.67–0.98) 0.84 (0.68–1.03) 0.85 (0.69–1.07)
1.45 (1.25–1.67) 1.60 (1.37–1.88) 1.77 (1.49–2.10) 1.96 (1.62–2.36)
1.08 (0.93–1.26) 1.16 (0.99–1.37) 1.25 (1.05–1.49) 1.35 (1.12–1.63)
0.52 (0.46–0.57) 0.53 (0.47–0.59) 0.54 (0.48–0.62) 0.56 (0.49–0.64)
Fig. 3. Cumulative risk of death from breast cancer (continuous line) and lung cancer (dashed line) up to 80 years of age (2013 versus 2020).
J.C. Martín-Sánchez et al. / Cancer Epidemiology 43 (2016) 22–29 27available scientiﬁc evidence does not support the implementation
of population screening programs for this type of cancer [44], but
there is strong evidence for smoking cessation programs. A
systematic review showed that interventions combining
pharmacotherapy and behavioral support increase smoking
cessation success in a wide range of populations, in comparison
to the usual care [45]. The systematic review included some
Spanish studies which showed good results after 1 year of
treatment [46,47]  one study with diabetics and the other with
the general population  and in both cases more than 20% of the
sample intervened was not smoking 1 year later. Even when the
program is successful in a minority of the participants, there is an
effect on mortality [48]. Also, former smokers who stopped less
than 10 years previously have a risk of LC decreased by one third
[49] and a similar risk to non-smokers after more than 20 years of
not smoking [50]. In this sense, the use of electronic cigarettes
(e-cigarettes) could be a useful tool to quit or reduce tobacco
consumption. However, current scientiﬁc evidence on the
effectiveness of e-cigarettes for quitting smoking is contradictory
and scarce. A meta-analysis [51] based on 13 studies (two
randomized controlled trials and 11 cohort studies) has failed to
prove that e-cigarettes help smokers to stop smoking in the long
term compared with placebo e-cigarettes, and that e-cigarettes
could help prevent relapse among former smokers or that they
could promote smoking cessation among current smokers.
Furthermore, other studies [52] found a high percentage of “dual”
use (i.e. use of e-cigarettes plus use of other tobacco products),
including in Spain [53,54].
Taking advantage of the infrastructure and coverage of BC
screening, we recommend including initiatives in this program to
reduce smoking, the main risk factor for LC, among women.Moreover, breast cancer screening could be an appropriate
“teachable moment” [55] to promote healthy behaviors such as
quitting smoking among women. For these reasons, we suggest
that combining both programs (tobacco cessation and breast
cancer screening) could be useful in reducing lung cancer. These
initiatives should not be targeted for early detection of the disease,
but for the primary prevention of the disease. Most ex-smokers
quit smoking without treatment, but there are effective treatments
for smokers who need help [56]. Brief counseling and behavioral
interventions can be effective, and there are also effective
medications, such as nicotine replacement products. Both
counseling and medication are effective, even more so when used
together [56]. A limitation of this intervention is that it could not
avoid the majority of the deaths by LC in the ﬁrst years, as the
women involved may have been exposed to tobacco for decades.
However, starting the intervention at 45 years of age when the risk
is starting to increase should be beneﬁcial in the long term: some
deaths by LC will be avoided, and some others will be delayed.
While there is no proposal of a better LC screening program,
especially with a smaller number of false-positive tests, smoking
cessation remains the most important approach to reduce LC
mortality.
The strength of this study is the validity and reliability of the data
recorded by the INE. Some studies on the accuracy of cancer death
have shown that these data cannot always be trusted, but BC and LC
are among the well-certiﬁed cancers, with a conﬁrmation rate and a
detection rate >90% [57]. The mortality registry is complete and
covers all Spanish territories. This avoids the inherent problems of
working with a sample. A weakness of the study is the use of
mortality as an indicator of the presence of the disease, which would
be accurate for a cancer with a low survival rate (lung) but not for one
28 J.C. Martín-Sánchez et al. / Cancer Epidemiology 43 (2016) 22–29with a high survival rate (breast) [58]. Therefore the outcome of
interest must be mortality, and we should not consider it a
replacement for the incidence, as these data are not available. We
used a simple log-linear Poisson model to obtain projections in
which the main assumption of this model is that log-linear trends
will continue into the future [24]. More complex models can be used,
such as age–period–cohort models, but these require a long period of
observation as a basis for prediction and may in practice present
difﬁculties in interpretation, with wider credible or prediction
intervals than those based on simple linear or log-linear models [24].
In addition, we performed short-term projections, up to the year
2020, and a simple log-linear modelwould performbetter than other
models in this particular situation [26,59].
In conclusion, the LC mortality rates are expected to exceed the
rates for BC in the next few years. The BC screening program in
Spain could be a helpful tool, as it has full coverage in the territory,
a high participation rate, and is indicated in an age group that
coincides with the moment when LC mortality strongly increases.
BC screening offers a good opportunity to implement measures to
help dependent women smokers quit smoking, in addition to
public health national campaigns.
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